Article
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies.
The Lancet. Oncology - 1 Aug 2009
Klug Stefanie J, Ressing Meike, Koenig Jochem, Abba Martin C, Agorastos Theodoros, Brenna Sylvia M F, Ciotti Marco, Das B R, Del Mistro Annarosa, Dybikowska Aleksandra, Giuliano Anna R, Gudleviciene Zivile, Gyllensten Ulf, Haws Andrea L F, Helland Aslaug, Herrington C Simon, Hildesheim Alan, Humbey Olivier, Jee Sun H, Kim Jae Weon, Madeleine Margaret M, Menczer Joseph, Ngan Hextan Y S, Nishikawa Akira, Niwa Yoshimitsu, Pegoraro Rosemary, Pillai M R, Ranzani Gulielmina, Rezza Giovanni, Rosenthal Adam N, Roychoudhury Susanta, Saranath Dhananjaya, Schmitt Virginia M, Sengupta Sharmila, Settheetham-Ishida Wannapa, Shirasawa Hiroshi, Snijders Peter J F, Stoler Mark H, Suárez-Rincón Angel E, Szarka Krisztina, Tachezy Ruth, Ueda Masatsugu, van der Zee Ate G J, von Knebel Doeberitz Magnus, Wu Ming-Tsang, Yamashita Tsuyoshi, Zehbe Ingeborg, Blettner Maria
Abstract excerpt
BACKGROUND: Cervical cancer is caused primarily by human papillomaviruses (HPV). The polymorphism rs1042522 at codon 72 of the TP53 tumour-suppressor gene has been investigated as a genetic cofactor. More than 80 studies were done between 1998 and 2006, after it was initially reported that women who are homozygous for the arginine allele had a risk for cervical cancer seven times higher than women who were...
Read the complete abstract on PubMed